• Thursday, October 17, 2024

News

4.3
Dye & Durham Prioritizes Reducing Leverage Ratio
News

Dye & Durham Prioritizes Reducing Leverage Ratio

Dye & Durham announces focus on reducing leverage ratio, shares surge; company successfully reduces total debt by 45 million Canadian dollars since Ju...

4.9
On the Beach Group Wins Landmark Court Case Against Ryanair
News

On the Beach Group Wins Landmark Court Case Against Ryanair

On the Beach Group emerges victorious in a legal battle against Ryanair, obtaining a £2 million judgment in its favor for flight refunds amidst the CO...

5.0
Bitcoin Holds Steady as Analysts Turn Bullish on Ether
News

Bitcoin Holds Steady as Analysts Turn Bullish on Ether

Bitcoin maintains its stability while analysts express positive outlook for Ether's growth in the market. Bitcoin ETF hopes, price fluctuations, and t...

4.5
Kintara Therapeutics Shifts Focus Following Disappointing Brain Cancer Study
News

Kintara Therapeutics Shifts Focus Following Disappointing Brain Cancer Study

San Diego-based biopharmaceutical company Kintara Therapeutics shifts focus from brain-cancer treatment to breast-cancer treatment after disappointing...

4.5
Treasury Department to Borrow $750 Billion in Q4
News

Treasury Department to Borrow $750 Billion in Q4

The Treasury Department plans to borrow $750 billion in the fourth quarter of this year, lower than previous estimates. Economists express concerns ov...

4.7
Safestyle UK Appoints Administrators
News

Safestyle UK Appoints Administrators

Door-and-window manufacturer Safestyle UK appoints administrators, resulting in redundancies and impacting subsidiaries. High cost inflation, economic...

4.5
Challenges and Ambitions: Elon Musk's Impact on X
News

Challenges and Ambitions: Elon Musk's Impact on X

Elon Musk's tenure at X (formerly Twitter) has faced challenges, with mixed outcomes. Despite a decline in valuation, Musk has ambitious plans to comp...

4.4
VYNE Therapeutics Receives Positive Data from Phase 1b Trial
News

VYNE Therapeutics Receives Positive Data from Phase 1b Trial

VYNE Therapeutics receives positive data from Phase 1b trial for VYN201, boosting investor confidence. Promising preclinical results for VYN202 also h...

4.9
Swiss Carbon Project Developer South Pole Terminates Kariba REDD+ Project in Zimbabwe
News

Swiss Carbon Project Developer South Pole Terminates Kariba REDD+ Project in Zimbabwe

Swiss carbon project developer South Pole withdraws from Kariba REDD+ project in Zimbabwe due to concerns about project standards and allegations agai...

4.4
VivoPower to Spin Off Caret Business Unit's Portfolio
News

VivoPower to Spin Off Caret Business Unit's Portfolio

VivoPower International will spin off most of its Caret business unit's solar project portfolio, providing shareholders with a special dividend in sto...